Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Plasma cell 2Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 3102Precursor Cell Lymphoblastic Leukemia-Lymphoma 2086Leukemia 2013Leukemia, Lymphocytic, Chronic, B-Cell 1771Myelodysplastic Syndromes 1298Hematologic Neoplasms 1067Lymphoma 1029Lymphoma, Non-Hodgkin 981Leukemia, Myelogenous, Chronic, BCR-ABL Positive 713Lymphoma, Follicular 704Lymphoma, Mantle-Cell 678Lymphoma, Large B-Cell, Diffuse 657Burkitt Lymphoma 642Multiple Myeloma 639Lymphoma, B-Cell, Marginal Zone 599Recurrence 587Hodgkin Disease 575Leukemia, Myelomonocytic, Chronic 495Lymphoma, Large-Cell, Immunoblastic 419Neoplasms 402Myeloproliferative Disorders 402Leukemia, Myeloid, Chronic-Phase 391Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 382Congenital Abnormalities 357Waldenstrom Macroglobulinemia 330Blast Crisis 324Leukemia, Myeloid, Accelerated Phase 290Lymphoma, T-Cell, Cutaneous 280Primary Myelofibrosis 270Anemia, Refractory, with Excess of Blasts 251

Interventions

ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Fractures, Spontaneous × Other hematologic neoplasm × Clear all
NCT01447914 2019-08-28

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 11 charts
Classical hematologyOther hematologic neoplasmPlasma cell

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡